The United Kingdom has brought into force the largest package of clinical trials reforms in more than 20 years, with regulators saying the changes will speed up access to new treatments while keeping patient safety at the centre of research.
In a statement published on 28 April 2026, the Health Research Authority and the Medicines and Healthcare products Regulatory Agency said the updated framework introduces faster assessment for first-in-human trials, a new fast-track route for lower-risk studies, and quicker approval for eligible modifications. The aim is to make it simpler to start and run research across the UK, especially in areas where time-to-treatment can shape patient outcomes. HRA announcement
What the new rules change for researchers and patients
According to the HRA, the reforms also embrace new approaches such as the use of early safety data from overseas studies that meet UK standards, as well as computer model simulations to help predict how medicines may behave before they are tested in patients. The regulator said the changes are designed to strengthen support for early-stage research and improve patient care by reducing delays.
The updated system follows progress already made in cutting UK clinical trial set-up times. The HRA said the average time for commercial interventional trials going through combined safety and ethical review has fallen from 169 days to 122 days, while the Combined Review process now takes an average of 41 days. Officials said this means the government’s 150-day target has been exceeded.
Greater transparency is now built into the framework
The new regulations also make registration of clinical trials and publication of summary results a legal requirement for the first time. The HRA said the safety of trial participants remains the priority, but the framework is intended to deliver faster approvals and a more proportionate process for lower-risk research.
Among the operational changes is Route B, a substantial modification pathway that was piloted between October 2025 and March 2026. During the pilot, applications were processed in an average of just seven calendar days, and more than half of registrations came from commercial sponsors. Under the new rules, eligible modifications can be automatically approved unless concerns are raised within 14 calendar days.
A wider push to make the UK more competitive for medical research
Officials said the reforms are meant to support the government’s wider ambition to make the UK a leading destination for medical research and life sciences investment. The HRA said the updated framework should help patients reach innovative medicines earlier, while also making the system simpler for sponsors, clinicians and researchers to navigate.
For the health sector, the change marks a significant shift in how studies will be set up and amended in the months ahead. For patients, the immediate promise is straightforward: quicker access to promising treatments, delivered through a system designed to stay rigorous, but move faster. Operational changes overview
